Filing Details

Accession Number:
0001209191-18-053539
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-10-02 21:41:14
Reporting Period:
2018-09-28
Accepted Time:
2018-10-02 21:41:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1724344 Entasis Therapeutics Holdings Inc. ETTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1202793 Michael Powell C/o Sofinnova Ventures, Inc
3000 Sand Hill Road, Bldg. 4, Suite 250
Menlo Park CA 94025
No No Yes No
1245624 James Healy C/o Sofinnova Ventures, Inc.
3000 Sand Hill Road, Bldg. 4, Suite 250
Menlo Park CA 94025
No No Yes No
1590102 Anand Mehra C/o Sofinnova Ventures, Inc.
3000 Sand Hill Road, Bldg. 4, Suite 250
Menlo Park CA 94025
No No Yes No
1612133 Sofinnova Venture Partners Ix, L.p. C/o Sofinnova Ventures, Inc.
3000 Sand Hill Road, Bldg. 4, Suite 250
Menlo Park CA 94025
No No Yes No
1612134 Sofinnova Management Ix, L.l.c. C/o Sofinnova Ventures, Inc.
3000 Sand Hill Road, Bldg. 4, Suite 250
Menlo Park CA 94025
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-09-28 359,267 $0.00 359,267 No 4 C Direct
Common Stock Acquisiton 2018-09-28 458,425 $0.00 842,454 No 4 C Direct
Common Stock Acquisiton 2018-09-28 337,724 $15.00 1,180,178 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B-1 Tranche A Convertible Preferred Stock Disposition 2018-09-28 7,446,904 $0.00 359,267 $0.00
Common Stock Series B-1 Tranche B Convertible Preferred Stock Disposition 2018-09-28 9,502,249 $0.00 458,425 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
  2. The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein.
  3. This number includes an aggregate of 24,762 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018.